PCN70 Cost Effectiveness Analysis Based on Progression Free Survival (PFS) of Pazopanib Versus Sunitinib for the Treatment of Advanced Renal Cell Carcinoma (ARCC) in the Mexican Context
Jun 1, 2012, 00:00 AM
10.1016/j.jval.2012.03.1187
https://www.valueinhealthjournal.com/article/S1098-3015(12)01252-1/fulltext
Section Title :
Cancer
Section Order :
714
First Page :
A220
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)01252-1&doi=10.1016/j.jval.2012.03.1187